PMC:7170368 / 9320-9957 JSONTXT

Annnotations TAB JSON ListView MergeView

    LitCovid-PubTator

    {"project":"LitCovid-PubTator","denotations":[{"id":"266","span":{"begin":353,"end":356},"obj":"Gene"},{"id":"267","span":{"begin":357,"end":360},"obj":"Gene"},{"id":"268","span":{"begin":364,"end":368},"obj":"Gene"},{"id":"269","span":{"begin":136,"end":140},"obj":"Species"},{"id":"270","span":{"begin":418,"end":426},"obj":"Species"},{"id":"271","span":{"begin":480,"end":488},"obj":"Species"},{"id":"272","span":{"begin":610,"end":618},"obj":"Species"},{"id":"273","span":{"begin":65,"end":77},"obj":"Disease"},{"id":"274","span":{"begin":88,"end":99},"obj":"Disease"},{"id":"275","span":{"begin":207,"end":219},"obj":"Disease"},{"id":"276","span":{"begin":224,"end":249},"obj":"Disease"},{"id":"277","span":{"begin":405,"end":417},"obj":"Disease"},{"id":"278","span":{"begin":458,"end":470},"obj":"Disease"},{"id":"279","span":{"begin":471,"end":479},"obj":"Disease"},{"id":"280","span":{"begin":601,"end":609},"obj":"Disease"},{"id":"281","span":{"begin":624,"end":636},"obj":"Disease"}],"attributes":[{"id":"A266","pred":"tao:has_database_id","subj":"266","obj":"Gene:1636"},{"id":"A267","pred":"tao:has_database_id","subj":"267","obj":"Gene:283"},{"id":"A268","pred":"tao:has_database_id","subj":"268","obj":"Gene:185"},{"id":"A269","pred":"tao:has_database_id","subj":"269","obj":"Tax:333278"},{"id":"A270","pred":"tao:has_database_id","subj":"270","obj":"Tax:9606"},{"id":"A271","pred":"tao:has_database_id","subj":"271","obj":"Tax:9606"},{"id":"A272","pred":"tao:has_database_id","subj":"272","obj":"Tax:9606"},{"id":"A273","pred":"tao:has_database_id","subj":"273","obj":"MESH:D006973"},{"id":"A274","pred":"tao:has_database_id","subj":"274","obj":"MESH:D055370"},{"id":"A275","pred":"tao:has_database_id","subj":"275","obj":"MESH:D006973"},{"id":"A276","pred":"tao:has_database_id","subj":"276","obj":"MESH:D011014"},{"id":"A277","pred":"tao:has_database_id","subj":"277","obj":"MESH:D006973"},{"id":"A278","pred":"tao:has_database_id","subj":"278","obj":"MESH:D006973"},{"id":"A279","pred":"tao:has_database_id","subj":"279","obj":"MESH:C000657245"},{"id":"A280","pred":"tao:has_database_id","subj":"280","obj":"MESH:C000657245"},{"id":"A281","pred":"tao:has_database_id","subj":"281","obj":"MESH:D006973"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"It was reported that the RAS plays a critical role in regulating hypertension and acute lung injury caused by viruses, such as SARS and H7N9 [5,7]. Changes in RAS activity are related to the pathogenesis of hypertension and inflammatory lung disease. Targeting RAS is an effective antihypertension therapeutic strategy. ACEIs and ARB, which inhibit the ACE/Ang II/AT1R system, are commonly used drugs for hypertensive patients. Recent evidence suggests that hypertensive COVID-19 patients are predisposed to develop severe cases [1]. Thus, it is important to determine the effect of RAS inhibitors on COVID-19 patients with hypertension."}

    MyTest

    {"project":"MyTest","denotations":[{"id":"32228222-16007097-27780684","span":{"begin":142,"end":143},"obj":"16007097"}],"namespaces":[{"prefix":"_base","uri":"https://www.uniprot.org/uniprot/testbase"},{"prefix":"UniProtKB","uri":"https://www.uniprot.org/uniprot/"},{"prefix":"uniprot","uri":"https://www.uniprot.org/uniprotkb/"}],"text":"It was reported that the RAS plays a critical role in regulating hypertension and acute lung injury caused by viruses, such as SARS and H7N9 [5,7]. Changes in RAS activity are related to the pathogenesis of hypertension and inflammatory lung disease. Targeting RAS is an effective antihypertension therapeutic strategy. ACEIs and ARB, which inhibit the ACE/Ang II/AT1R system, are commonly used drugs for hypertensive patients. Recent evidence suggests that hypertensive COVID-19 patients are predisposed to develop severe cases [1]. Thus, it is important to determine the effect of RAS inhibitors on COVID-19 patients with hypertension."}

    LitCovid-PD-FMA-UBERON

    {"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T25","span":{"begin":88,"end":92},"obj":"Body_part"},{"id":"T26","span":{"begin":237,"end":241},"obj":"Body_part"}],"attributes":[{"id":"A25","pred":"fma_id","subj":"T25","obj":"http://purl.org/sig/ont/fma/fma7195"},{"id":"A26","pred":"fma_id","subj":"T26","obj":"http://purl.org/sig/ont/fma/fma7195"}],"text":"It was reported that the RAS plays a critical role in regulating hypertension and acute lung injury caused by viruses, such as SARS and H7N9 [5,7]. Changes in RAS activity are related to the pathogenesis of hypertension and inflammatory lung disease. Targeting RAS is an effective antihypertension therapeutic strategy. ACEIs and ARB, which inhibit the ACE/Ang II/AT1R system, are commonly used drugs for hypertensive patients. Recent evidence suggests that hypertensive COVID-19 patients are predisposed to develop severe cases [1]. Thus, it is important to determine the effect of RAS inhibitors on COVID-19 patients with hypertension."}

    LitCovid-PD-UBERON

    {"project":"LitCovid-PD-UBERON","denotations":[{"id":"T21","span":{"begin":25,"end":28},"obj":"Body_part"},{"id":"T22","span":{"begin":88,"end":92},"obj":"Body_part"},{"id":"T23","span":{"begin":159,"end":162},"obj":"Body_part"},{"id":"T24","span":{"begin":237,"end":241},"obj":"Body_part"},{"id":"T25","span":{"begin":261,"end":264},"obj":"Body_part"},{"id":"T26","span":{"begin":583,"end":586},"obj":"Body_part"}],"attributes":[{"id":"A21","pred":"uberon_id","subj":"T21","obj":"http://purl.obolibrary.org/obo/UBERON_0018229"},{"id":"A22","pred":"uberon_id","subj":"T22","obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"A23","pred":"uberon_id","subj":"T23","obj":"http://purl.obolibrary.org/obo/UBERON_0018229"},{"id":"A24","pred":"uberon_id","subj":"T24","obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"A25","pred":"uberon_id","subj":"T25","obj":"http://purl.obolibrary.org/obo/UBERON_0018229"},{"id":"A26","pred":"uberon_id","subj":"T26","obj":"http://purl.obolibrary.org/obo/UBERON_0018229"}],"text":"It was reported that the RAS plays a critical role in regulating hypertension and acute lung injury caused by viruses, such as SARS and H7N9 [5,7]. Changes in RAS activity are related to the pathogenesis of hypertension and inflammatory lung disease. Targeting RAS is an effective antihypertension therapeutic strategy. ACEIs and ARB, which inhibit the ACE/Ang II/AT1R system, are commonly used drugs for hypertensive patients. Recent evidence suggests that hypertensive COVID-19 patients are predisposed to develop severe cases [1]. Thus, it is important to determine the effect of RAS inhibitors on COVID-19 patients with hypertension."}

    LitCovid-PD-MONDO

    {"project":"LitCovid-PD-MONDO","denotations":[{"id":"T77","span":{"begin":65,"end":77},"obj":"Disease"},{"id":"T78","span":{"begin":82,"end":99},"obj":"Disease"},{"id":"T80","span":{"begin":93,"end":99},"obj":"Disease"},{"id":"T81","span":{"begin":127,"end":131},"obj":"Disease"},{"id":"T82","span":{"begin":207,"end":219},"obj":"Disease"},{"id":"T83","span":{"begin":237,"end":249},"obj":"Disease"},{"id":"T84","span":{"begin":330,"end":333},"obj":"Disease"},{"id":"T85","span":{"begin":471,"end":479},"obj":"Disease"},{"id":"T86","span":{"begin":601,"end":609},"obj":"Disease"},{"id":"T87","span":{"begin":624,"end":636},"obj":"Disease"}],"attributes":[{"id":"A77","pred":"mondo_id","subj":"T77","obj":"http://purl.obolibrary.org/obo/MONDO_0005044"},{"id":"A78","pred":"mondo_id","subj":"T78","obj":"http://purl.obolibrary.org/obo/MONDO_0006502"},{"id":"A79","pred":"mondo_id","subj":"T78","obj":"http://purl.obolibrary.org/obo/MONDO_0015796"},{"id":"A80","pred":"mondo_id","subj":"T80","obj":"http://purl.obolibrary.org/obo/MONDO_0021178"},{"id":"A81","pred":"mondo_id","subj":"T81","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A82","pred":"mondo_id","subj":"T82","obj":"http://purl.obolibrary.org/obo/MONDO_0005044"},{"id":"A83","pred":"mondo_id","subj":"T83","obj":"http://purl.obolibrary.org/obo/MONDO_0005275"},{"id":"A84","pred":"mondo_id","subj":"T84","obj":"http://purl.obolibrary.org/obo/MONDO_0012733"},{"id":"A85","pred":"mondo_id","subj":"T85","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A86","pred":"mondo_id","subj":"T86","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A87","pred":"mondo_id","subj":"T87","obj":"http://purl.obolibrary.org/obo/MONDO_0005044"}],"text":"It was reported that the RAS plays a critical role in regulating hypertension and acute lung injury caused by viruses, such as SARS and H7N9 [5,7]. Changes in RAS activity are related to the pathogenesis of hypertension and inflammatory lung disease. Targeting RAS is an effective antihypertension therapeutic strategy. ACEIs and ARB, which inhibit the ACE/Ang II/AT1R system, are commonly used drugs for hypertensive patients. Recent evidence suggests that hypertensive COVID-19 patients are predisposed to develop severe cases [1]. Thus, it is important to determine the effect of RAS inhibitors on COVID-19 patients with hypertension."}

    LitCovid-PD-CLO

    {"project":"LitCovid-PD-CLO","denotations":[{"id":"T79","span":{"begin":35,"end":36},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T80","span":{"begin":88,"end":92},"obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"T81","span":{"begin":88,"end":92},"obj":"http://www.ebi.ac.uk/efo/EFO_0000934"},{"id":"T82","span":{"begin":110,"end":117},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T83","span":{"begin":163,"end":171},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T84","span":{"begin":237,"end":241},"obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"T85","span":{"begin":237,"end":241},"obj":"http://www.ebi.ac.uk/efo/EFO_0000934"}],"text":"It was reported that the RAS plays a critical role in regulating hypertension and acute lung injury caused by viruses, such as SARS and H7N9 [5,7]. Changes in RAS activity are related to the pathogenesis of hypertension and inflammatory lung disease. Targeting RAS is an effective antihypertension therapeutic strategy. ACEIs and ARB, which inhibit the ACE/Ang II/AT1R system, are commonly used drugs for hypertensive patients. Recent evidence suggests that hypertensive COVID-19 patients are predisposed to develop severe cases [1]. Thus, it is important to determine the effect of RAS inhibitors on COVID-19 patients with hypertension."}

    LitCovid-PD-CHEBI

    {"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T94","span":{"begin":25,"end":28},"obj":"Chemical"},{"id":"T95","span":{"begin":159,"end":162},"obj":"Chemical"},{"id":"T96","span":{"begin":261,"end":264},"obj":"Chemical"},{"id":"T97","span":{"begin":320,"end":325},"obj":"Chemical"},{"id":"T98","span":{"begin":361,"end":363},"obj":"Chemical"},{"id":"T99","span":{"begin":395,"end":400},"obj":"Chemical"},{"id":"T100","span":{"begin":583,"end":586},"obj":"Chemical"},{"id":"T101","span":{"begin":587,"end":597},"obj":"Chemical"}],"attributes":[{"id":"A94","pred":"chebi_id","subj":"T94","obj":"http://purl.obolibrary.org/obo/CHEBI_63620"},{"id":"A95","pred":"chebi_id","subj":"T95","obj":"http://purl.obolibrary.org/obo/CHEBI_63620"},{"id":"A96","pred":"chebi_id","subj":"T96","obj":"http://purl.obolibrary.org/obo/CHEBI_63620"},{"id":"A97","pred":"chebi_id","subj":"T97","obj":"http://purl.obolibrary.org/obo/CHEBI_35457"},{"id":"A98","pred":"chebi_id","subj":"T98","obj":"http://purl.obolibrary.org/obo/CHEBI_74067"},{"id":"A99","pred":"chebi_id","subj":"T99","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A100","pred":"chebi_id","subj":"T100","obj":"http://purl.obolibrary.org/obo/CHEBI_63620"},{"id":"A101","pred":"chebi_id","subj":"T101","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"}],"text":"It was reported that the RAS plays a critical role in regulating hypertension and acute lung injury caused by viruses, such as SARS and H7N9 [5,7]. Changes in RAS activity are related to the pathogenesis of hypertension and inflammatory lung disease. Targeting RAS is an effective antihypertension therapeutic strategy. ACEIs and ARB, which inhibit the ACE/Ang II/AT1R system, are commonly used drugs for hypertensive patients. Recent evidence suggests that hypertensive COVID-19 patients are predisposed to develop severe cases [1]. Thus, it is important to determine the effect of RAS inhibitors on COVID-19 patients with hypertension."}

    LitCovid-PD-GO-BP

    {"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T1","span":{"begin":191,"end":203},"obj":"http://purl.obolibrary.org/obo/GO_0009405"}],"text":"It was reported that the RAS plays a critical role in regulating hypertension and acute lung injury caused by viruses, such as SARS and H7N9 [5,7]. Changes in RAS activity are related to the pathogenesis of hypertension and inflammatory lung disease. Targeting RAS is an effective antihypertension therapeutic strategy. ACEIs and ARB, which inhibit the ACE/Ang II/AT1R system, are commonly used drugs for hypertensive patients. Recent evidence suggests that hypertensive COVID-19 patients are predisposed to develop severe cases [1]. Thus, it is important to determine the effect of RAS inhibitors on COVID-19 patients with hypertension."}

    LitCovid-sentences

    {"project":"LitCovid-sentences","denotations":[{"id":"T78","span":{"begin":0,"end":147},"obj":"Sentence"},{"id":"T79","span":{"begin":148,"end":250},"obj":"Sentence"},{"id":"T80","span":{"begin":251,"end":319},"obj":"Sentence"},{"id":"T81","span":{"begin":320,"end":427},"obj":"Sentence"},{"id":"T82","span":{"begin":428,"end":533},"obj":"Sentence"},{"id":"T83","span":{"begin":534,"end":637},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"It was reported that the RAS plays a critical role in regulating hypertension and acute lung injury caused by viruses, such as SARS and H7N9 [5,7]. Changes in RAS activity are related to the pathogenesis of hypertension and inflammatory lung disease. Targeting RAS is an effective antihypertension therapeutic strategy. ACEIs and ARB, which inhibit the ACE/Ang II/AT1R system, are commonly used drugs for hypertensive patients. Recent evidence suggests that hypertensive COVID-19 patients are predisposed to develop severe cases [1]. Thus, it is important to determine the effect of RAS inhibitors on COVID-19 patients with hypertension."}

    LitCovid-PD-HP

    {"project":"LitCovid-PD-HP","denotations":[{"id":"T19","span":{"begin":65,"end":77},"obj":"Phenotype"},{"id":"T20","span":{"begin":82,"end":99},"obj":"Phenotype"},{"id":"T21","span":{"begin":207,"end":219},"obj":"Phenotype"},{"id":"T22","span":{"begin":237,"end":249},"obj":"Phenotype"},{"id":"T23","span":{"begin":624,"end":636},"obj":"Phenotype"}],"attributes":[{"id":"A19","pred":"hp_id","subj":"T19","obj":"http://purl.obolibrary.org/obo/HP_0000822"},{"id":"A20","pred":"hp_id","subj":"T20","obj":"http://www.orpha.net/ORDO/Orphanet_178320"},{"id":"A21","pred":"hp_id","subj":"T21","obj":"http://purl.obolibrary.org/obo/HP_0000822"},{"id":"A22","pred":"hp_id","subj":"T22","obj":"http://purl.obolibrary.org/obo/HP_0002088"},{"id":"A23","pred":"hp_id","subj":"T23","obj":"http://purl.obolibrary.org/obo/HP_0000822"}],"text":"It was reported that the RAS plays a critical role in regulating hypertension and acute lung injury caused by viruses, such as SARS and H7N9 [5,7]. Changes in RAS activity are related to the pathogenesis of hypertension and inflammatory lung disease. Targeting RAS is an effective antihypertension therapeutic strategy. ACEIs and ARB, which inhibit the ACE/Ang II/AT1R system, are commonly used drugs for hypertensive patients. Recent evidence suggests that hypertensive COVID-19 patients are predisposed to develop severe cases [1]. Thus, it is important to determine the effect of RAS inhibitors on COVID-19 patients with hypertension."}

    2_test

    {"project":"2_test","denotations":[{"id":"32228222-16007097-27780684","span":{"begin":142,"end":143},"obj":"16007097"}],"text":"It was reported that the RAS plays a critical role in regulating hypertension and acute lung injury caused by viruses, such as SARS and H7N9 [5,7]. Changes in RAS activity are related to the pathogenesis of hypertension and inflammatory lung disease. Targeting RAS is an effective antihypertension therapeutic strategy. ACEIs and ARB, which inhibit the ACE/Ang II/AT1R system, are commonly used drugs for hypertensive patients. Recent evidence suggests that hypertensive COVID-19 patients are predisposed to develop severe cases [1]. Thus, it is important to determine the effect of RAS inhibitors on COVID-19 patients with hypertension."}